News

Global COVID-19 Summit brings new policy, financial commitments to whole-of-society pandemic preparations

At the second Global COVID-19 Summit last week, governments, including the United States, pledged to provide $3.2 billion in additional funds for COVID-19 and other pandemic preparedness needs and committed to expanding and accelerating testing and vaccine access.

This year’s summit was led by the United States, Belize, Germany, Indonesia, and Senegal, who declared advancements throughout the health security chain to be possible but not guaranteed, and something that will require greater political and financial commitments. In particular, this is true for the protection of society’s most vulnerable.

The summit identified three major needs going forward:

  1. Prioritizing high-risk populations
  2. Expanding access to COVID-19 and other pandemic countermeasures
  3. Maintaining pandemic response and preparedness

While the pandemic, they emphasized, is not over, SARS-CoV-2 is also not going away. At this point, world leaders are focused on reducing it to a manageable respiratory pathogen, even if it remains a global phenomenon. Of the new monetary pledges meant to help achieve this, nearly $2.5 billion will go toward COVID-19 and related response activities, while $712 million will go toward a new pandemic preparedness and global health security fund at the World Bank. Inequities remain even so, and leaders floated the potential to create regional hubs to help pandemic preparedness and response and find sustainable and predictable solutions for early warning systems. 

The World Health Organization’s (WHO) 70 percent global vaccination target remains the major goal, and since the first Global COVID-19 Summit, the world’s vaccination rate has increased from 33 percent to nearly 60 percent. 

The United States committed an additional $200 million to the pandemic preparedness and global health security financial fund at the World Bank. Next year, the budget proposed by President Biden calls for another $4.75 billion for that fund. The nation is also committed to sharing COVID-19 vaccine-related intellectual property and research tools, rapidly reviewing generic products used for global COVID-19 response, and piloting test and treatment strategies for the most vulnerable populations in low and middle-income countries. 

Chris Galford

Recent Posts

BARDA, French partner Crossject to develop needle-free ZENEO midazolam autoinjectors

In an effort to stock up for emergencies involving nerve agents, the Biomedical Advanced Research…

21 hours ago

Sens. Warner, Baldwin lead effort advocating domestically made masks purchases

A group of lawmakers recently forwarded correspondence to the Centers for Medicare and Medicaid Services…

21 hours ago

DHS S&T, Israel National Cyber Directorate detail cybersecurity collaboration

The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) and Israel National…

21 hours ago

Collaborative, NIH-funded research develops fast, cheap genotyping approach to detect SARS-CoV-2 variants

The efforts of an interdisciplinary research team funded by the National Institutes of Health’s Rapid…

21 hours ago

Raytheon touts Valiant Shield 22 demonstration results

Aerospace and defense company Raytheon Technologies is touting the accomplishments of its subsidiary, Raytheon Intelligence…

5 days ago

DOJ forms collaborative New England Prescription Opioid Strike Force in focus on illegal opioid prescriptions

Struggling to contain a national opioid epidemic, the United States Justice Department (DOJ) Criminal Division…

5 days ago

This website uses cookies.